Table 10.

This table shows the evidence board’s belief criteria strategy. The columns next to each assertion type indicate the LOE group and specific LOE that the evidence-board chose as the type’s belief criteria. There are two columns because the DIKB allows the belief criterion for supporting evidence to be different than the belief criterion for refuting evidence. Note that the belief criterion for supporting evidence is the same as the belief criterion for refuting evidence for all but the inhibits and does-not-inhibit assertion types. Assertion types indicated as default assumptions are noted separately because the system uses them for inference even if their evidence does not meet belief criteria

Assertion types not used as default assumptions
Assertion type	Evidence for	Evidence against
bioavailability	A, LOE-1	A, LOE-1
maximum-concentration	A, LOE-1	A, LOE-1
first-pass-effect	B, LOE-1	B, LOE-1
fraction-absorbed	B, LOE-1	B, LOE-1
primary-total-clearance-mechanism	C, LOE-1	C, LOE-1
controls-formation-of	D, LOE-1	D, LOE-1
substrate-of	D, LOE-1	D, LOE-1
is-not-substrate-of	D, LOE-1	D, LOE-1
primary-total-clearance-enzyme	E, LOE-1	E, LOE-1
primary-metabolic-clearance-enzyme	F, LOE-1	F, LOE-1
has-metabolite	G, LOE-1	G, LOE-1
inhibition-constant	H, LOE-1	H, LOE-1
inhibits	I, LOE-1	J, LOE-1
does-not-inhibit	J, LOE-1	I, LOE-1

Assertion types used as default assumptions
permanently-deactivates-catalytic-function	K, LOE-1	K, LOE-1
does-not-permanently-deactivate-catalytic-function	K, LOE-1	K, LOE-1
in-vitro-probe-substrate-of-enzyme	K, LOE-1	K, LOE-1
in-vitro-selective-inhibitor-of-enzyme	L, LOE-1	L, LOE-1
in-viVo-selective-inhibitor-of-enzyme	M, LOE-1	M, LOE-1
sole-PK-effect-alter-metabolic-clearance	M, LOE-1	M, LOE-1
pceut-entity-of-concern	N, LOE-1	N, LOE-1
polymorphic-enzyme	O, LOE-1	O, LOE-1